Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 3/10

vs
industry
vs
history
Cash-to-Debt 0.07
BIOS's Cash-to-Debt is ranked lower than
74% of the 267 Companies
in the Global Medical Care industry.

( Industry Median: 0.37 vs. BIOS: 0.07 )
Ranked among companies with meaningful Cash-to-Debt only.
BIOS' s Cash-to-Debt Range Over the Past 10 Years
Min: 0  Med: 0.41 Max: No Debt
Current: 0.07
Equity-to-Asset -0.13
BIOS's Equity-to-Asset is ranked lower than
96% of the 261 Companies
in the Global Medical Care industry.

( Industry Median: 0.50 vs. BIOS: -0.13 )
Ranked among companies with meaningful Equity-to-Asset only.
BIOS' s Equity-to-Asset Range Over the Past 10 Years
Min: -0.18  Med: 0.42 Max: 0.75
Current: -0.13
-0.18
0.75
Debt-to-Equity -6.14
BIOS's Debt-to-Equity is ranked lower than
99.99% of the 193 Companies
in the Global Medical Care industry.

( Industry Median: 0.63 vs. BIOS: -6.14 )
Ranked among companies with meaningful Debt-to-Equity only.
BIOS' s Debt-to-Equity Range Over the Past 10 Years
Min: -22.1  Med: 0.12 Max: 2.05
Current: -6.14
-22.1
2.05
Debt-to-EBITDA 24.18
BIOS's Debt-to-EBITDA is ranked lower than
97% of the 197 Companies
in the Global Medical Care industry.

( Industry Median: 2.82 vs. BIOS: 24.18 )
Ranked among companies with meaningful Debt-to-EBITDA only.
BIOS' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -17.97  Med: 4.98 Max: 36.84
Current: 24.18
-17.97
36.84
Interest Coverage 0.18
BIOS's Interest Coverage is ranked lower than
99% of the 224 Companies
in the Global Medical Care industry.

( Industry Median: 7.55 vs. BIOS: 0.18 )
Ranked among companies with meaningful Interest Coverage only.
BIOS' s Interest Coverage Range Over the Past 10 Years
Min: 0.18  Med: 0.63 Max: 8.06
Current: 0.18
0.18
8.06
Piotroski F-Score: 3
Altman Z-Score: 0.15
Beneish M-Score: -3.03
WACC vs ROIC
7.15%
2.42%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating Margin % 0.99
BIOS's Operating Margin % is ranked lower than
77% of the 267 Companies
in the Global Medical Care industry.

( Industry Median: 7.34 vs. BIOS: 0.99 )
Ranked among companies with meaningful Operating Margin % only.
BIOS' s Operating Margin % Range Over the Past 10 Years
Min: -7.33  Med: 0.76 Max: 4.61
Current: 0.99
-7.33
4.61
Net Margin % -8.42
BIOS's Net Margin % is ranked lower than
86% of the 267 Companies
in the Global Medical Care industry.

( Industry Median: 4.16 vs. BIOS: -8.42 )
Ranked among companies with meaningful Net Margin % only.
BIOS' s Net Margin % Range Over the Past 10 Years
Min: -30.51  Med: -4.86 Max: 10.9
Current: -8.42
-30.51
10.9
ROA % -12.23
BIOS's ROA % is ranked lower than
89% of the 269 Companies
in the Global Medical Care industry.

( Industry Median: 3.45 vs. BIOS: -12.23 )
Ranked among companies with meaningful ROA % only.
BIOS' s ROA % Range Over the Past 10 Years
Min: -44.23  Med: -8.06 Max: 20.26
Current: -12.23
-44.23
20.26
ROC (Joel Greenblatt) % -10.54
BIOS's ROC (Joel Greenblatt) % is ranked lower than
86% of the 269 Companies
in the Global Medical Care industry.

( Industry Median: 14.51 vs. BIOS: -10.54 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
BIOS' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -76.36  Med: 4.07 Max: 17.14
Current: -10.54
-76.36
17.14
3-Year Revenue Growth Rate -2.60
BIOS's 3-Year Revenue Growth Rate is ranked lower than
80% of the 209 Companies
in the Global Medical Care industry.

( Industry Median: 7.70 vs. BIOS: -2.60 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
BIOS' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -35  Med: 4.5 Max: 15.9
Current: -2.6
-35
15.9
3-Year EPS without NRI Growth Rate -25.40
BIOS's 3-Year EPS without NRI Growth Rate is ranked lower than
83% of the 163 Companies
in the Global Medical Care industry.

( Industry Median: 7.00 vs. BIOS: -25.40 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
BIOS' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -82.7  Med: -21.5 Max: 502.8
Current: -25.4
-82.7
502.8
GuruFocus has detected 6 Warning Signs with BioScrip Inc BIOS.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» BIOS's 30-Y Financials

Financials (Next Earnings Date: 2018-03-02)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q4 2016

BIOS Guru Trades in Q4 2016

Mario Gabelli 1,157,601 sh (+32.28%)
Pioneer Investments 280,320 sh (unchged)
Diamond Hill Capital 5,305,400 sh (-0.02%)
» More
Q1 2017

BIOS Guru Trades in Q1 2017

Pioneer Investments 280,320 sh (unchged)
Diamond Hill Capital 5,151,236 sh (-2.91%)
Mario Gabelli 926,551 sh (-19.96%)
» More
Q2 2017

BIOS Guru Trades in Q2 2017

Pioneer Investments 280,320 sh (unchged)
Mario Gabelli 868,451 sh (-6.27%)
Diamond Hill Capital 4,270,069 sh (-17.11%)
» More
Q3 2017

BIOS Guru Trades in Q3 2017

Paul Tudor Jones 57,054 sh (New)
Chuck Royce 175,000 sh (New)
Pioneer Investments 280,320 sh (unchged)
Mario Gabelli 812,851 sh (-6.40%)
Diamond Hill Capital 3,801,126 sh (-10.98%)
» More
» Details

Insider Trades

Latest Guru Trades with BIOS

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Mario Gabelli 2017-09-30 Reduce -6.40%$2.35 - $3.25 $ 2.48-12%812,851
Mario Gabelli 2017-06-30 Reduce -6.27%$1.4 - $2.99 $ 2.4832%868,451
Mario Gabelli 2017-03-31 Reduce -19.96%$1.26 - $2.27 $ 2.4850%926,551
Mario Gabelli 2016-12-31 Add 32.28%$1.02 - $3.33 $ 2.4829%1,157,601
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Health Care Providers » Medical Care    NAICS: 621610    SIC: 8082
Compare:HKSE:02389, XTER:MED, CAI:CLHO.CA, ASX:VRT, HKSE:02120, HKSE:01509, OTCPK:AVCO, XKLS:101, NSE:HCG, TSX:DR, HKSE:00286, XLIS:LUZ, ISX:SAME, OHEL:PIHLIS, SGX:588, LSE:ANCR, BKK:NTV, SGX:QC7, BKK:RJH, HKSE:03869 » details
Traded in other countries:MM6.Germany,
Headquarter Location:USA
BioScrip Inc provides home infusion & other home healthcare services to patients, physicians, hospitals, healthcare payors & pharmaceutical manufacturers to provide clinical management solutions & delivers cost-effective access to medications.

BioScrip Inc provides home infusion & other home healthcare services to patients, physicians, hospitals, healthcare payors & pharmaceutical manufacturers to provide clinical management solutions & delivers cost-effective access to medications.

Ratios

vs
industry
vs
history
PS Ratio 0.32
BIOS's PS Ratio is ranked higher than
92% of the 259 Companies
in the Global Medical Care industry.

( Industry Median: 1.70 vs. BIOS: 0.32 )
Ranked among companies with meaningful PS Ratio only.
BIOS' s PS Ratio Range Over the Past 10 Years
Min: 0.04  Med: 0.25 Max: 1.89
Current: 0.32
0.04
1.89
EV-to-EBIT -83.41
BIOS's EV-to-EBIT is ranked lower than
99.99% of the 209 Companies
in the Global Medical Care industry.

( Industry Median: 20.85 vs. BIOS: -83.41 )
Ranked among companies with meaningful EV-to-EBIT only.
BIOS' s EV-to-EBIT Range Over the Past 10 Years
Min: -233  Med: 2.4 Max: 9138.1
Current: -83.41
-233
9138.1
EV-to-EBITDA 38.48
BIOS's EV-to-EBITDA is ranked lower than
94% of the 227 Companies
in the Global Medical Care industry.

( Industry Median: 15.17 vs. BIOS: 38.48 )
Ranked among companies with meaningful EV-to-EBITDA only.
BIOS' s EV-to-EBITDA Range Over the Past 10 Years
Min: -135.9  Med: 15.9 Max: 121
Current: 38.48
-135.9
121
EV-to-Revenue 0.84
BIOS's EV-to-Revenue is ranked higher than
84% of the 265 Companies
in the Global Medical Care industry.

( Industry Median: 2.18 vs. BIOS: 0.84 )
Ranked among companies with meaningful EV-to-Revenue only.
BIOS' s EV-to-Revenue Range Over the Past 10 Years
Min: 0.1  Med: 0.7 Max: 3
Current: 0.84
0.1
3
Current Ratio 1.91
BIOS's Current Ratio is ranked higher than
66% of the 253 Companies
in the Global Medical Care industry.

( Industry Median: 1.41 vs. BIOS: 1.91 )
Ranked among companies with meaningful Current Ratio only.
BIOS' s Current Ratio Range Over the Past 10 Years
Min: 0.86  Med: 1.35 Max: 2.76
Current: 1.91
0.86
2.76
Quick Ratio 1.60
BIOS's Quick Ratio is ranked higher than
59% of the 253 Companies
in the Global Medical Care industry.

( Industry Median: 1.31 vs. BIOS: 1.60 )
Ranked among companies with meaningful Quick Ratio only.
BIOS' s Quick Ratio Range Over the Past 10 Years
Min: 0.79  Med: 1.17 Max: 2.5
Current: 1.6
0.79
2.5
Days Inventory 19.10
BIOS's Days Inventory is ranked lower than
52% of the 199 Companies
in the Global Medical Care industry.

( Industry Median: 16.86 vs. BIOS: 19.10 )
Ranked among companies with meaningful Days Inventory only.
BIOS' s Days Inventory Range Over the Past 10 Years
Min: 11.42  Med: 20.93 Max: 80.5
Current: 19.1
11.42
80.5
Days Sales Outstanding 37.23
BIOS's Days Sales Outstanding is ranked lower than
51% of the 220 Companies
in the Global Medical Care industry.

( Industry Median: 41.26 vs. BIOS: 37.23 )
Ranked among companies with meaningful Days Sales Outstanding only.
BIOS' s Days Sales Outstanding Range Over the Past 10 Years
Min: 36.18  Med: 47.85 Max: 178.08
Current: 37.23
36.18
178.08
Days Payable 26.01
BIOS's Days Payable is ranked lower than
65% of the 159 Companies
in the Global Medical Care industry.

( Industry Median: 51.14 vs. BIOS: 26.01 )
Ranked among companies with meaningful Days Payable only.
BIOS' s Days Payable Range Over the Past 10 Years
Min: 19.73  Med: 32.58 Max: 109.18
Current: 26.01
19.73
109.18

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -20.00
BIOS's 3-Year Average Share Buyback Ratio is ranked lower than
82% of the 159 Companies
in the Global Medical Care industry.

( Industry Median: -2.50 vs. BIOS: -20.00 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
BIOS' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -20  Med: -10.15 Max: -0.5
Current: -20
-20
-0.5

Valuation & Return

vs
industry
vs
history
Price-to-Median-PS-Value 1.37
BIOS's Price-to-Median-PS-Value is ranked lower than
75% of the 232 Companies
in the Global Medical Care industry.

( Industry Median: 1.03 vs. BIOS: 1.37 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
BIOS' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.21  Med: 0.94 Max: 6.11
Current: 1.37
0.21
6.11
Earnings Yield (Greenblatt) % -1.18
BIOS's Earnings Yield (Greenblatt) % is ranked lower than
82% of the 269 Companies
in the Global Medical Care industry.

( Industry Median: 3.79 vs. BIOS: -1.18 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
BIOS' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -84.9  Med: 0.8 Max: 47.8
Current: -1.18
-84.9
47.8
Forward Rate of Return (Yacktman) % -11.13
BIOS's Forward Rate of Return (Yacktman) % is ranked lower than
88% of the 128 Companies
in the Global Medical Care industry.

( Industry Median: 8.93 vs. BIOS: -11.13 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
BIOS' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: -16.4  Med: -1.8 Max: 1.3
Current: -11.13
-16.4
1.3

More Statistics

Revenue (TTM) (Mil) $874.73
EPS (TTM) $ -0.68
Beta0.38
Short Percentage of Float12.11%
52-Week Range $0.98 - 3.39
Shares Outstanding (Mil)127.52

Analyst Estimate

Dec17 Dec18
Revenue (Mil $) 805 695
EPS ($) -0.37 -0.22
EPS without NRI ($) -0.37 -0.22
EPS Growth Rate
(Future 3Y To 5Y Estimate)
12.00%
Dividends per Share ($)

Piotroski F-Score Details

Piotroski F-Score: 33
Positive ROAN
Positive CFROAN
Higher ROA yoyN
CFROA > ROAY
Lower Leverage yoyN
Higher Current Ratio yoyY
Less Shares Outstanding yoyN
Higher Gross Margin yoyY
Higher Asset Turnover yoyN

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}